达利雷生在失眠治疗中的应用及详细疗效解读

Introduction: DaliRasen belongs to a class of drugs called orexin receptor antagonists. Its function is to block the action of certain natural substances in the brain that cause awakening. It is clinically used to treat insomnia. It can effectively improve sleep disorders, improve sleep quality, and also improve the patient's overall quality of life.

Efficacy of DaliRazen

It is a new dual orexin receptor antagonist that has shown efficacy in the treatment of insomnia in multiple randomized clinical trials. Insomnia involves difficulty sleeping, including difficulty falling asleep, difficulty staying asleep, waking up early, and feeling tired during the day. Insomnia is generally divided into acute or short-term sleep disorders (<3 months) and chronic sleep disorders (more than 3 months). Orexin receptors 1 and 2 are promising targets for treating insomnia. Dalitrazolin is a novel dual orexin receptor antagonist approved by the U.S. Food and Drug Administration for the treatment of insomnia. Studies show that Dalitrazolin significantly improves sleep onset and sleep maintenance, thereby improving daytime function.

Treatment effect analysis

DaliRasen is an effective choice for the treatment of insomnia and has shown efficacy in young and old people. It antagonizes orexin receptors, thereby reducing arousal drive. DaliRasen is the first dual orexin receptor antagonist approved in the EU for the treatment of chronic insomnia and has been approved in the United States for the treatment of insomnia.

In a Phase 3 clinical trial, dalirasin dose-dependently improved objective latency to sustained sleep, objective wake time after sleep onset, subjective total sleep time, and subjective daytime function at the 50 mg dose compared with placebo.

Safety Analysis

DaliRasen is generally well tolerated. Adverse events (AEs) commonly associated with insomnia medications, such as drowsiness, fatigue, and dizziness, occurred at similar or slightly higher rates with dalirasam compared with placebo. Falls occurred with similar or lower frequency in the DaliRasen group than in the placebo group. Most adverse events were mild in severity and incidence was not dose dependent. In the 12-month extension trial, the efficacy of dalirasam was maintained and no new safety or tolerability issues emerged.

Usage and Dosage

The correct usage of Dalilaysan is to take it orally once every night before going to bed. It should be taken within 30 minutes before going to bed, so that the drug can play a sleep-promoting effect during the expected sleep time. If taken after a meal or shortly after a meal, it may cause a delay in falling asleep.

Precautions

DaliRasen is contraindicated in patients with narcolepsy. Use is not recommended in patients with severe hepatic impairment, whereas a lower maximum dose is recommended in patients with moderate hepatic impairment. In addition, attention should also be paid to the drug interactions of daliramson. It is not recommended and should be avoided to use daliramson with strong CYP3A4 inhibitors and moderately strong CYP3A4 inducers to avoid affecting the therapeutic effect and causing adverse reactions.